Recruiting studies: Potentially Resectable Hepatocellular Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of P
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07012798 Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06041477 Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Poten
Phase 2/Phase 3 · 2 location(s) · Shanghai Zhongshan Hospital · NCT06796803 SIRT for Potentially Resectable HCC
NA · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05994859 A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Ther
NA · 1 location(s) · Li Qiang · NCT07070076

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.